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Children with musculoskeletal conditions experience muscle weakness, diﬃculty walking and limitations in physical activities.
Standardtreatmentincludes physiotherapy, casting, andsurgery.Theuseofbotulinumtoxinsappearsasa promisingtreatmenton
itsown,butusuallyasanadjuncttoothertreatmentmodalitiesandasanalternativetosurgery.Theobjectivesweretoestablishthe
evidence on the eﬀectiveness, safety and functional outcome of BTX-A in children with musculoskeletal conditions. A literature
search using ﬁve electronic databases identiﬁed 24 studies that met our inclusion criteria. Two randomized clinical trials were
included; most studies were case studies with small sample sizes and no control group. Improvements in gait pattern, function,
range of motion, reduction of co-contractions, and avoidance of surgical procedures were found following BTX-A injections.
Adverse events were not reported in 10 studies, minor adverse events were reported in 13 children and there were no severe adverse
events. Additional doses appear safe. BTX-A is a promising treatment adjunct in improving functional outcomes in children
with musculoskeletal conditions. Future studies including larger samples, longer follow-up periods and a comparison group are
required to provide evidence on the eﬀectiveness and safety of this drug in children with musculoskeletal conditions.
1.Introduction
Thousands of children and adolescents across the United
States suﬀer from musculoskeletal conditions each year
[1, 2]. Common musculoskeletal conditions in children
include cerebral palsy (CP), congenital muscular torticollis
(CMT), Duchenne muscular dystrophy, idiopathic clubfoot,
idiopathic toe walking (ITW), Legg-Calv´ e-Perthes disease
(LCPD), limb length discrepancy, and neonatal brachial
plexus palsy (NBPP). Musculoskeletal abnormalities and
deformities can deprive children of physical activities, child-
hood experiences, and a healthy lifestyle. Besides the physical
and psychosocial burden these conditions and injuries place
on the child and family, these conditions also incur a ﬁnan-
cial burden for the patient and the healthcare system as
multiple hospital visits are often required.
Proper and timely treatment including standard ap-
proachessuchasphysiotherapy,casting,bracing,andsurgery
is essential to ensure the child optimal growth and devel-
opment. Besides these traditional modalities, the use of
botulinum toxins appears as a promising treatment on its
own, as an adjunct to other treatment modalities and as
an alternative to surgery. Several authors have suggested the
use of BTX-A in children with musculoskeletal conditions,
yet the evidence supporting its safety and eﬀectiveness is
not well established. The use of BTX-A in children with
CP has been widely documented [3–5] and is beyond
the scope of this paper. The objectives of this systematic
review were to establish the evidence on the eﬀectiveness,
safety, and functional outcome of BTX-A in children with
musculoskeletal conditions.
1.1. Mechanisms of Action of Botulinum Toxins. Botulinum
toxin is an extremely potent, naturally occurring poison
resulting from the fermentation of the anaerobic spore-
forming bacterium Clostridium botulinum. These toxins2 International Journal of Pediatrics
cause ﬂaccid paralysis by blocking acetylcholine release,
which is required for muscle contraction at the neuromus-
cular junction. Thus, the toxins have the capacity to reduce
muscular activity in a dose-dependent manner. Muscle
weakness occurs within a few days to one week after local
injection, peaks within two weeks for several weeks, and
then plateaus in milder form (the desired clinical eﬀect)
before gradually returning to baseline [6]. Clinically, this
chemodenervation with muscle relaxation lasts between 12
and 16 weeks [7]. Recovery from the toxin-induced paralysis
begins with resprouting of axon terminals and slow recovery
of the neurons ability to release acetylcholine, which results
in nerve conduction to be reestablished.
Clinical observations suggest that these neurotoxins have
three mechanisms of action: paralytic, antisecretory, and
analgesic (antinociceptive). A number of studies suggest
that several pathways play a role in the analgesic eﬀects
of botulinum toxins, such as in conditions of pathologic
muscle overactivity (dystonia and spasticity) [8] and in the
role of the calcitonin gene-related peptide in the aﬀerent
signaling of pain [9]. The most eﬀective dose is unknown
although recommendations have been given [10]. The FDA
has approved a total-body dose of 400units administered
every 12 to 16weeks or at longer intervals to avoid toxicity.
Identifying the appropriate muscle sites for injection is done
through palpation, electrical stimulation, electromyography,
ultrasound, ﬂuoroscopy, and computerized tomography
dependingonthemusclesizeandlocation.Aneedlebetween
23 and 27gauge is selected based on muscle depth, diﬃculty
palpating the muscle, and use of electromyography. Injec-
tions may be administered under local anesthesia, conscious
sedation, or general anesthesia [11].
1.2. Botulinum Toxin Serotypes. There are seven diﬀerent
serotypes of the neurotoxin, named botulinum toxin (BTX)
types A to G. Although they all inhibit acetylcholine release
from nerve terminals, they diﬀer according to their intracel-
lular protein targets, potency, dosing, and duration of eﬀect.
BTX-A is the serotype that has been most studied in terms
of therapeutic application. BTX-B and BTX-F have also been
used in clinical practice, but are less potent than BTX-A, and
have a shorter duration of action [12]. BTX-B has also been
shown to have regional and systemic anticholinergic adverse
side eﬀects, which limits its clinical use [4].
There are currently three types A and one type B
brand of botulinum toxins available in the US market.
In 2010, the US Food and Drug Administration (FDA)
announced generic names for all of the versions of injectable
botulinum toxins. This change in terminology is expected
to diﬀerentiate between these diﬀerent brands and provide
each brand with its own identity thereby improving its
clinical use and reducing errors and misinterpretation.
Hence, OnabotulinumtoxinA (Botox by Allergan INC in the
United States), AbobotulinumtoxinA (Dysport by Ipsen in
France), IncobotulinumtoxinA (Xeomin by Merz Pharma-
ceuticals GmbH in Germany), and RimabotulinumtoxinB
(Myobloc/NeuroblocbySolsticeNeurosciencesintheUnited
States) are the new four generic names used in the USA.
These new generic names have not yet been adopted by other
regulatory agencies [13].
1.3. Clinical Use of Botulinum Toxin Type A. BTX-A was ﬁrst
approved by the FDA in 1989 for the treatment of strabismus
and blepharospasm (two eye muscle disorders), making it
the ﬁrst botulinum toxin type A product approved in the
world. In the USA, BTX-A is also approved to treat cervical
dystonia and severe primary axillary hyperhidrosis in adults
[13]. Recently, the FDA has also approved the use of BTX-
A to treat increased muscle stiﬀness in the elbow, wrist,
and ﬁnger muscles in adults with upper limb spasticity. In
addition to its therapeutic uses, the same formulation of
BTX-A was approved by the FDA in 2002 under the trade
name Botox Cosmetic to improve the look of facial wrinkles
in adults less than 65years of age. BTX-A is one of the most
widely researched medicines in the world.
Although the use of BTX-A has not yet been approved
for use in children, it has been used in a variety of clinical
conditions both for its neuromuscular and analgesic eﬀects
due to its safe, predictable, and reversible eﬀects on motor
weakness. These oﬀ-label indications include CMT, CP,
idiopathic clubfoot, ITW, LCPD, lower limb lengthening and
NBPP [14]. BTX-A is used in these children to decrease
spasticity, manage postoperative pain, and improve quality
of life. The most common use of BTX-A in children is for the
treatment of spasticity in CP [15]. Studies have shown that
BTX-A decreases muscle tone in children with upper and
lower limbs spasticity associated with CP [4]a n dc a nh e l p
prevent the development of muscle contractures and bony
deformities [16], as well as improve upper limb movement
and function [15–17]. Patient selection, BTX-A dosing,
dilutionandadministration,identiﬁcationofmusclegroups,
and outcome measurement must be carefully considered
[13, 16].
1.4. Adverse Events. Adverse events following botulinum
toxin injection have been found to be mild, temporary, as
well as dose and site related [12]. These may include local
reactions, such as bruising and pain at the site of injec-
tion, excessive localized muscle weakness, and incontinence.
Systemic eﬀects are very rare [18] and may include ﬂu-
like symptoms, headaches, light-headedness, fever, chills,
hypertension, diarrhea and abdominal pain, generalized
weakness, dysphagia, dry mouth, and subsequent aspiration.
These are far less common, are generally short-lived, and
may result from the systemic spread of the toxin to adjacent
muscles. A boxed warning label describing the spread of
the toxin and its potentially life-threatening eﬀects appears
on the labels following the death of a child following BTX-
A injections [13]. However, until today, no causal relation-
ship conﬁrmed the evidence relating this speciﬁc adverse
event to the toxins [14]. Caution should be exerted when
injecting BTX-A in children with preexisting swallowing
or respiratory problems. Since all botulinum neurotoxins
are proteins, immunoresistance may develop secondary to
antibody formation. The incidence of antibody-mediated
resistance in long-term treated patients ranges from 3 toInternational Journal of Pediatrics 3
23%, depending on the patient sample, treatment regimen
and toxin preparation [7] .Ar e c e n tA u s t r a l i a ns t u d y[ 19]
prospectively documented the presence of adverse events in
334 children with CP in the month before and in the month
after BTX-A injection. They found that the children had
signiﬁcant morbidities prior to the injection, adverse events
were present in 23.2% of children, and no deaths occurred.
1.5. Congenital Muscular Torticollis. CMT is common and
refers to unilateral contracture of the sternocleidomastoid
muscle that restricts the infant’s range of motion at the neck.
Infants with CMT display head tilt toward the shortened
side, which is often combined with rotation of the head
to the opposite side [20, 21]. It is reported to occur in
1 infant in every 250–300 live births [21, 22]. Manual
stretching is still the most common form of treatment,
and about 90% of CMT resolves with stretching exercises
[22]. When conservative treatment is ineﬀective, surgery is
considered. However, as an alternative to invasive surgical
intervention, BTX-A may be an option to increase the
eﬀectiveness of stretching on the side of the contracture and
allow strengthening of overstretched and weakened muscles
on the opposite side of the neck [12, 21, 22].
1.6. Duchenne Muscular Dystrophy. It is a progressive X-
linked recessive disorder and is caused by a defective gene for
dystrophin aﬀecting approximately 1 out of every 3,600 male
infants. Muscle tissue is replaced by adipose and connective
tissue [23]. The proximal muscles of the lower extremities
are aﬀected ﬁrst, with decreased range of motion, ﬂexion
contracture of the hip and knee, and extension contracture
of the ankle. Symptoms usually appear before age 6 and
typically include fatigue, muscle weakness, and progressive
diﬃculty in walking. Braces may improve mobility and self-
carefunction, and a wheelchairisoftenused byage12. There
is no known cure for Duchenne muscular dystrophy and by
the late teens or twenties the condition is severe enough to
shortenlifeexpectancy.Treatmentaimstocontrolsymptoms
to maximize quality of life and maintain muscle strength
and function. BTX-A may be indicated to decrease muscle
contractures of the lower extremities and facilitate standing
and mobility [14].
1.7. Idiopathic Clubfoot. In this congenital deformity, the
hindfoot is in equinovarus and the midfoot and forefoot
are adducted and supinated. Approximately 50% of cases of
clubfoot are bilateral. The exact etiology remains unknown,
although numerous factors have been implicated. Clubfoot
is one of the most common birth defects, occurring in 1–3
per 1000 live births. A child with an untreated clubfoot will
walk on the outer edge of the foot instead of the sole, develop
painful callosities, be unable to wear shoes, and have painful
feet that often limit activity. Nonsurgical modalities include
serial manipulation and casting, such as Ponseti’s technique
[24, 25], as well as taping, physical therapy, and continuous
passive motion. Surgery is indicated if satisfactory clinical
and radiographic correction by nonsurgical methods is not
obtained. BTX-A injection into the child’s calf muscle is
indicated to facilitate nonsurgical techniques, to supplement
surgical release and to serve as an alternative to Achilles
tendon lengthening by reducing the tone in the most con-
tracted muscles [12, 14].
1.8. Idiopathic Toe Walking. This condition is present in
children older than 3years of age still walking on their
toes without any neurological, orthopaedic, or psychiatric
diseases. ITW has been estimated to occur in 7 to 24% of
thechildhoodpopulation [26].Treatmentrecommendations
include physical therapy, casting, bracing, surgical release,
and Achilles tendon lengthening [14]. BTX-A may be useful
to manage the contractures in cases in which toe walking
recurs despite conservative and surgical treatment.
1.9. Legg-Calv´ e-Perthes Disease. LCPD is a degenerative dis-
ease of the hip joint aﬀecting about 10.8 children of 100,000
childrenandismorecommoninboys[27].Itischaracterized
by an interruption of the blood supply of the head of the
femur with loss of bone mass and joint deformity at the hip.
The disease is typically found in young children, and it can
lead to osteoarthritis in adults. Common symptoms include
hip, knee, or groin pain, exacerbated by hip/leg movement,
reduced range of motion at the hip and painful and limping
gait.Physicalactivitysuchasstanding,walking,running,and
kneeling may cause severe irritation or inﬂammation of the
damaged area. The goal of treatment is to prevent deformity
of the femoral head [27] and avoid severe degenerative
arthritislateron.BTX-Amaybeindicatedtoweakenselected
muscles to restore muscle balance at the hip joint [14].
1.10. Lower Limb Lengthening. Children undergoing lower
limb lengthening using an external ﬁxator exhibit excellent
results in most cases, yet the postoperative pain can be
signiﬁcant and often requires prolonged use of analgesics
and even narcotics [28, 29]. Other aspects of the limb
lengthening, such as the osteotomy and incision sites,
gradual distraction increasing soft tissue tension, range of
motion exercises, and gait training result in ongoing pain
for weeks after the application. Appropriate pain manage-
ment is essential for optimal quality of life and functional
outcomes in children undergoing limb lengthening. BTX-
A has been shown to reduce postoperative pain in chil-
dren secondary to reduced muscle spasm [12]a n dm a y
be indicated in children undergoing lower limb lengthen-
ing to alleviate spasm and pain during the lengthening
process.
1.11. Neonatal Brachial Plexus Palsy. NBPP is deﬁned as a
ﬂaccid paresis of the upper extremity secondary to unwanted
muscularcocontractionorinappropriateactivationofantag-
onist muscles due to increased forces of distraction to
the neck during delivery. Associated injuries may include
fractures to the clavicle and humerus, facial nerve palsy,
and torticollis. Incidence varies between 0.38 and 3per 1000
live births in industrialized countries and occurs more fre-
quently in infants born over 4kg, breech deliveries, maternal
diabetes, and vacuum/forceps extraction [30]. While early4 International Journal of Pediatrics
physical therapy yields complete return to function in many
infants, infants whose elbow ﬂexion and shoulder abduction
have not recovered before6 months are indicated for surgical
reconstruction of the brachial plexus [30]. A novel approach
for children with NBPP injuries is the therapeutic use of
BTX-A to inhibit unwanted cocontractions and activate
antagonist muscles. Early treatment of these children with
BTX-Ainjectionsmayalsoresultinstronger,normalmuscles
and may prevent the development of glenoid dysplasia
[12, 31].
2.MaterialsandMethods
A literature search using the electronic databases MEDLINE,
PubMed, Cochrane, Trip, and Web of Science for published
articles in English from 1980 to September 2011 was
conducted using botulinum toxin, congenital muscular tor-
ticollis, Duchenne muscular dystrophy, idiopathic clubfoot,
idiopathic toe walking, Legg-Calv´ e-Perthes disease, lower
limb lengthening, neonatal brachial plexus palsy, and rele-
vant search terms. To be included, a study had to be written
in English and to include children between 0 to 21years
of age with one of the above-mentioned musculoskeletal
conditions. Review articles, editorials, commentaries, and
conference proceedings were excluded. Research studies that
were included in this review were classiﬁed as levels I to
IV, based on the American Academy of Neurology (AAN)
levels of evidence. Data was independently extracted by two
reviewers (N. Dahan-Oliel and B. Kasaai).
3. Results
3.1. Search Results. The literature search yielded 791 hits,
which were then reviewed for eligibility. Twenty-four studies
met our inclusion criteria and were included in this review.
A ﬂow chart illustrates the search results in Figure 1.T h e
majority of studies were on children with NBPP (n = 10),
followed by idiopathic clubfoot (n = 5), CMT (n = 4),
ITW (n = 3), Duchenne muscular dystrophy (n = 1), and
lower limb lengthening (n = 1). No studies that looked
at the eﬀect of BTX-A in children with LCPD were found.
Findings are categorized by musculoskeletal condition and
are summarized in Table 1.
3.2. Congenital Muscular Torticollis. Four studies were in-
cluded. Two of these studies [32, 33] included both children
and adults but were included as separate results for children
were provided. In total, outcome was provided for forty-
ﬁve children aged 3months to 18years following BTX-A
injections. The following muscles were injected in isolation
or in combination: sternocleidomastoid, trapezius, splenius,
and scalenus. Head posture, cervical ROM, and pain were
most frequently assessed. Improvement was reported in 36
patients (80%). Adverse events were not reported in two
studies [32, 33]. Two studies reported mild dysphagia, neck
weakness, neck bruising and soreness, and brief fever follow-
ing injection in ﬁve children [34, 35]. There were variations
in BTX-A dosage, number of injections per muscle, length
Identiﬁcation
Records identiﬁed through
database searching
Additional records identiﬁed
Screening
Records screened after
duplicates removed
Records excluded
Eligibility
Full-text articles
assessed for eligibility
Full-text articles
Inclusion
Studies included in
systematic review
Reasons for exclusion:
Review of literature, commentary or editorial, 
not primarily empirical studies 
Not on target population
Did not provide outcome data after BTX-A injection
(n = 791)
through bibliography review (n = 2)
(n = 429)
(n = 371)
(n = 58)
excluded (n = 34)
(n = 24)
Figure 1
of follow-up, and outcomes assessed between studies as well
as within the same study, which limited comparability of
ﬁndings. Standardized outcome measures were not used. It
is diﬃcult to attribute clinical improvements to the BTX-A
treatment since the children in these studies often received
a combination of both BTX-A injections and physical
therapy. Furthermore, none of these studies compared BTX-
A treatment with either traditional treatment or surgical
treatment.Onestudyon15infantswhohadasigniﬁcantrisk
of progressing to surgery because of severe torticollis found
promising results. Indeed, only the oldest infant required
surgical release following BTX-A injections, while the other
14 infants showed signiﬁcantly improved neck ROM and
did not require surgery [35]. These ﬁndings suggest that
BTX-A may be a safe and eﬀective treatment modality when
traditional treatments (home program, physical therapy) do
not yield acceptable results. BTX-A treatment may obviate
surgical interventions in certain cases [35], but randomized
controlled trials with larger samples are needed to conﬁrm
this ﬁnding. Although it seems that the initial injections of
BTX-A should be administered at a young age, the exact age
is not yet established.
3.3. Duchenne Muscular Dystrophy. One study met the
inclusion criteria [36]. An 11-year-old boy was injectedInternational Journal of Pediatrics 5
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n
d
o
s
e
:
3
3
.
3
U
S
u
b
j
e
c
t
i
v
e
t
r
e
a
t
m
e
n
t
s
a
t
i
s
f
a
c
t
i
o
n
,
R
O
M
r
e
s
u
l
t
s
1
4
/
1
5
p
a
t
i
e
n
t
s
i
m
p
r
o
v
e
d
n
e
c
k
R
O
M
a
n
d
h
e
a
d
p
o
s
i
t
i
o
n
a
n
d
n
o
l
o
n
g
e
r
n
e
e
d
e
d
s
u
r
g
e
r
y
(
i
)
1
c
h
i
l
d
h
a
d
n
e
c
k
b
r
u
i
s
i
n
g
.
(
i
i
)
1
c
h
i
l
d
h
a
d
a
s
o
r
e
n
e
c
k
.
(
i
i
i
)
1
c
h
i
l
d
h
a
d
a
b
r
i
e
f
f
e
v
e
r
f
o
l
l
o
w
i
n
g
i
n
j
e
c
t
i
o
n
.
I
V
O
l
e
s
z
e
k
e
t
a
l
.
,
2
0
0
5
[
3
5
]
R
e
t
r
o
s
p
e
c
t
i
v
e
c
a
s
e
s
e
r
i
e
s
N
=
2
7
p
a
t
i
e
n
t
s
w
i
t
h
C
M
T
,
(
a
g
e
r
a
n
g
e
:
6
–
1
8
m
(
m
e
a
n
=
1
0
.
1
m
)
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
+
p
h
y
s
i
c
a
l
t
h
e
r
a
p
y
f
o
r
2
3
/
2
5
p
a
t
i
e
n
t
s
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
i
n
j
e
c
t
i
o
n
s
b
y
t
h
e
s
a
m
e
p
h
y
s
i
c
i
a
n
i
n
t
o
s
t
e
r
n
o
c
l
e
i
d
o
m
a
s
t
o
i
d
o
r
u
p
p
e
r
t
r
a
p
e
z
i
u
s
m
u
s
c
l
e
,
o
r
b
o
t
h
3
c
h
i
l
d
r
e
n
r
e
c
e
i
v
e
d
r
e
p
e
a
t
i
n
j
e
c
t
i
o
n
s
.
D
o
s
a
g
e
:
b
a
s
e
d
o
n
a
g
e
a
n
d
m
u
s
c
l
e
s
i
z
e
R
a
n
g
e
2
0
–
5
0
U
/
m
u
s
c
l
e
Q
u
a
l
i
t
a
t
i
v
e
c
o
m
m
e
n
t
s
b
y
p
h
y
s
i
c
i
a
n
’
s
o
b
s
e
r
v
a
t
i
o
n
Q
u
a
n
t
i
t
a
t
i
v
e
m
e
a
s
u
r
e
m
e
n
t
b
y
g
o
n
i
o
m
e
t
e
r
t
o
m
e
a
s
u
r
e
c
h
a
n
g
e
s
i
n
c
e
r
v
i
c
a
l
r
o
t
a
t
i
o
n
a
n
d
h
e
a
d
t
i
l
t
2
0
/
2
7
p
a
t
i
e
n
t
s
i
m
p
r
o
v
e
d
c
e
r
v
i
c
a
l
r
o
t
a
t
i
o
n
o
r
h
e
a
d
t
i
l
t
T
w
o
c
h
i
l
d
r
e
n
h
a
d
m
i
l
d
d
y
s
p
h
a
g
i
a
a
n
d
n
e
c
k
w
e
a
k
n
e
s
s
I
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T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
A
u
t
h
o
r
,
y
e
a
r
S
t
u
d
y
d
e
s
i
g
n
P
o
p
u
l
a
t
i
o
n
I
n
t
e
r
v
e
n
t
i
o
n
a
n
d
a
d
m
i
n
i
s
t
r
a
t
i
o
n
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
A
d
v
e
r
s
e
e
v
e
n
t
s
A
A
N
l
e
v
e
l
o
f
e
v
i
d
e
n
c
e
D
u
c
h
e
n
n
e
m
u
s
c
u
l
a
r
d
y
s
t
r
o
p
h
y
V
o
n
W
e
n
d
t
a
n
d
A
u
t
t
i
-
R
¨
a
m
¨
o
,
1
9
9
9
[
3
6
]
C
a
s
e
s
t
u
d
y
1
1
y
.
o
.
m
a
l
e
w
i
t
h
t
i
g
h
t
n
e
s
s
i
n
l
e
f
t
k
n
e
e
ﬂ
e
x
o
r
s
c
a
u
s
i
n
g
d
i
ﬃ
c
u
l
t
i
e
s
i
n
s
t
a
n
d
i
n
g
e
x
e
r
c
i
s
e
s
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
+
p
h
y
s
i
c
a
l
t
h
e
r
a
p
y
t
w
i
c
e
/
w
e
e
k
+
s
t
r
e
t
c
h
i
n
g
o
f
t
h
e
h
a
m
s
t
r
i
n
g
s
t
w
i
c
e
/
d
a
y
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
i
n
j
e
c
t
i
o
n
i
n
t
o
t
h
e
s
e
m
i
t
e
n
d
i
n
o
u
s
m
u
s
c
l
e
,
s
e
m
i
m
e
m
b
r
a
n
o
u
s
m
u
s
c
l
e
,
a
n
d
i
n
t
h
e
b
i
c
e
p
s
f
e
m
o
r
i
s
m
u
s
c
l
e
u
n
d
e
r
e
l
e
c
t
r
o
m
y
o
g
r
a
m
g
u
i
d
a
n
c
e
T
o
t
a
l
d
o
s
e
3
U
/
k
g
P
o
p
l
i
t
e
a
l
a
n
g
l
e
(
r
a
n
g
e
o
f
m
o
t
i
o
n
)
,
a
b
i
l
i
t
y
t
o
d
o
t
h
e
s
t
a
n
d
i
n
g
e
x
e
r
c
i
s
e
s
R
a
n
g
e
o
f
m
o
t
i
o
n
i
n
c
r
e
a
s
e
d
b
y
2
0
d
e
g
r
e
e
s
a
f
t
e
r
i
n
j
e
c
t
i
o
n
,
b
u
t
a
f
t
e
r
5
m
o
n
t
h
s
a
n
i
n
c
r
e
a
s
e
o
f
5
d
e
g
r
e
e
s
c
o
m
p
a
r
e
d
t
o
t
h
e
i
n
i
t
i
a
l
ﬁ
n
d
i
n
g
w
a
s
l
e
f
t
N
o
n
e
I
V
I
d
i
o
p
a
t
h
i
c
c
l
u
b
f
o
o
t
A
l
v
a
r
e
z
e
t
a
l
.
,
2
0
0
9
[
3
7
]
L
o
n
g
-
t
e
r
m
-
5
y
e
a
r
f
o
l
l
o
w
-
u
p
o
f
A
l
v
a
r
e
z
e
t
a
l
.
,
2
0
0
5
[
3
8
]
N
=
4
4
p
a
t
i
e
n
t
s
,
w
i
t
h
6
5
i
d
i
o
p
a
t
h
i
c
c
l
u
b
f
e
e
t
(
f
r
o
m
t
h
e
o
r
i
g
i
n
a
l
5
5
-
p
a
t
i
e
n
t
c
o
h
o
r
t
)
I
n
t
e
r
v
e
n
t
i
o
n
:
m
a
n
i
p
u
l
a
t
i
o
n
,
c
a
s
t
i
n
g
,
a
n
d
B
T
X
-
A
,
i
n
j
e
c
t
i
o
n
(
A
l
l
e
r
g
a
n
)
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
(
i
)
2
4
p
a
t
i
e
n
t
s
r
e
q
u
i
r
e
d
n
o
a
d
d
i
t
i
o
n
a
l
i
n
j
e
c
t
i
o
n
s
f
r
o
m
p
r
e
v
i
o
u
s
t
r
e
a
t
m
e
n
t
.
(
i
i
)
2
9
p
a
t
i
e
n
t
s
r
e
q
u
i
r
e
d
≥
2
i
n
j
e
c
t
i
o
n
s
.
P
a
s
s
i
v
e
a
n
k
l
e
R
O
M
D
o
r
s
i
ﬂ
e
x
i
o
n
w
i
t
h
9
0
-
d
e
g
r
e
e
ﬂ
e
x
i
o
n
(
D
F
F
)
,
w
i
t
h
k
n
e
e
i
n
f
u
l
l
e
x
t
e
n
s
i
o
n
(
D
F
E
)
,
p
l
a
n
t
a
r
ﬂ
e
x
i
o
n
,
a
n
d
h
e
e
l
b
i
s
e
c
t
o
r
O
v
e
r
t
h
e
f
o
l
l
o
w
-
u
p
:
(
i
)
T
r
e
a
t
e
d
c
l
u
b
f
e
e
t
m
a
i
n
t
a
i
n
e
d
a
D
F
F
≥
1
5
d
e
g
r
e
e
s
(
i
i
)
4
8
%
o
f
c
l
u
b
f
e
e
t
w
e
r
e
s
u
c
c
e
s
s
f
u
l
l
y
c
o
r
r
e
c
t
e
d
a
f
t
e
r
s
i
n
g
l
e
d
o
s
e
o
f
B
T
X
-
A
N
o
t
r
e
p
o
r
t
e
d
I
V
C
u
m
m
i
n
g
s
,
2
0
0
9
[
3
9
]
R
C
T
N
=
3
2
n
e
w
b
o
r
n
s
,
a
g
e
d
0
–
3
0
d
,
w
i
t
h
3
2
c
o
n
g
e
n
i
t
a
l
c
l
u
b
f
e
e
t
(
D
i
m
e
g
l
i
o
g
r
a
d
e
I
I
I
)
I
n
t
e
r
v
e
n
t
i
o
n
:
t
h
e
P
o
n
s
e
t
i
m
e
t
h
o
d
t
r
e
a
t
m
e
n
t
+
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
o
r
p
l
a
c
e
b
o
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
S
i
n
g
l
e
i
n
j
e
c
t
i
o
n
o
f
7
.
5
U
B
T
X
-
A
i
n
g
a
s
t
r
o
c
s
o
l
e
u
s
m
u
s
c
l
e
+
7
.
5
U
i
n
t
i
b
i
a
l
i
s
p
o
s
t
e
r
i
o
r
m
u
s
c
l
e
P
r
i
m
a
r
y
o
u
t
c
o
m
e
s
r
e
c
o
r
d
e
d
:
t
i
m
e
r
e
q
u
i
r
e
d
f
o
r
c
a
s
t
i
n
g
a
n
d
t
h
e
n
e
e
d
f
o
r
A
c
h
i
l
l
e
s
t
e
n
o
t
o
m
y
N
o
s
t
a
t
i
s
t
i
c
a
l
e
ﬀ
e
c
t
f
o
u
n
d
w
i
t
h
B
T
X
-
A
,
a
s
a
d
m
i
n
i
s
t
e
r
e
d
i
n
t
h
i
s
s
t
u
d
y
,
B
T
X
-
A
d
i
d
n
o
t
r
e
d
u
c
e
t
h
e
t
i
m
e
i
n
c
a
s
t
b
y
m
o
r
e
t
h
a
n
1
6
d
a
y
s
a
n
d
d
i
d
n
o
t
r
e
d
u
c
e
t
h
e
n
e
e
d
f
o
r
t
e
n
o
t
o
m
y
N
o
t
r
e
p
o
r
t
e
d
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T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
A
u
t
h
o
r
,
y
e
a
r
S
t
u
d
y
d
e
s
i
g
n
P
o
p
u
l
a
t
i
o
n
I
n
t
e
r
v
e
n
t
i
o
n
a
n
d
a
d
m
i
n
i
s
t
r
a
t
i
o
n
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
A
d
v
e
r
s
e
e
v
e
n
t
s
A
A
N
l
e
v
e
l
o
f
e
v
i
d
e
n
c
e
A
l
v
a
r
e
z
e
t
a
l
.
,
2
0
0
5
[
3
8
]
P
r
o
s
p
e
c
t
i
v
e
c
l
i
n
i
c
a
l
s
t
u
d
y
N
=
5
1
p
a
t
i
e
n
t
s
w
i
t
h
7
3
i
d
i
o
p
a
t
h
i
c
c
l
u
b
f
e
e
t
G
r
o
u
p
1
:
i
n
i
t
i
a
l
v
i
s
i
t
<
3
0
d
a
y
s
G
r
o
u
p
2
:
i
n
i
t
i
a
l
v
i
s
i
t
b
e
t
w
e
e
n
3
0
d
a
y
s
a
n
d
1
y
I
n
t
e
r
v
e
n
t
i
o
n
:
P
o
n
s
e
t
i
-
t
y
p
e
m
a
n
i
p
u
l
a
t
i
o
n
s
a
n
d
c
a
s
t
i
n
g
s
,
f
o
l
l
o
w
e
d
b
y
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
B
T
X
-
A
(
1
0
U
/
k
g
)
i
n
j
e
c
t
e
d
i
n
t
o
a
ﬀ
e
c
t
e
d
m
u
s
c
l
e
D
o
s
e
:
t
o
t
a
l
d
o
s
e
w
a
s
d
i
v
i
d
e
d
b
e
t
w
e
e
n
2
l
e
g
s
f
o
r
b
i
l
a
t
e
r
a
l
c
l
u
b
f
e
e
t
P
i
r
a
n
i
s
c
o
r
e
a
n
d
m
e
a
n
f
o
o
t
d
o
r
s
i
ﬂ
e
x
i
o
n
s
c
o
r
e
s
P
a
t
i
e
n
t
s
e
v
a
l
u
a
t
e
d
a
t
r
e
g
u
l
a
r
i
n
t
e
r
v
a
l
s
:
a
n
k
l
e
R
O
M
,
r
e
c
u
r
r
e
n
c
e
s
,
a
n
d
i
n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
r
e
c
u
r
r
e
n
c
e
s
(
i
)
5
0
/
5
1
p
a
t
i
e
n
t
s
h
a
d
s
u
c
c
e
s
s
f
u
l
a
t
t
e
n
u
a
t
i
o
n
o
f
t
r
i
c
e
p
s
s
u
r
a
e
c
o
m
p
l
e
x
w
i
t
h
m
a
j
o
r
i
m
p
r
o
v
e
m
e
n
t
i
n
m
e
a
n
f
o
o
t
d
o
r
s
i
ﬂ
e
x
i
o
n
s
c
o
r
e
a
f
t
e
r
B
T
X
-
A
.
(
i
i
)
P
i
r
a
n
i
s
c
o
r
e
s
a
l
s
o
r
e
d
u
c
e
d
a
f
t
e
r
B
T
X
-
A
b
y
4
.
4
5
a
n
d
3
,
i
n
g
r
o
u
p
1
,
a
n
d
2
,
r
e
s
p
e
c
t
i
v
e
l
y
.
(
i
i
i
)
M
e
a
n
f
o
l
l
o
w
-
u
p
:
1
2
m
o
n
t
h
s
±
3
m
o
n
t
h
s
.
N
o
n
e
I
I
I
M
i
t
c
h
e
l
l
e
t
a
l
.
,
2
0
0
4
[
4
0
]
P
r
e
l
i
m
i
n
a
r
y
r
e
p
o
r
t
N
=
3
p
a
t
i
e
n
t
s
(
a
g
e
r
a
n
g
e
:
1
2
-
1
3
m
)
w
h
o
u
n
d
e
r
w
e
n
t
s
u
r
g
e
r
y
b
u
t
w
i
t
h
r
e
c
u
r
r
e
n
t
d
e
f
o
r
m
i
t
y
3
–
6
m
o
n
t
h
s
a
f
t
e
r
i
n
d
e
x
p
r
o
c
e
d
u
r
e
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
+
m
o
l
d
e
d
p
l
a
s
t
e
r
c
a
s
t
s
.
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
i
n
j
e
c
t
i
o
n
i
n
t
o
m
u
s
c
l
e
g
r
o
u
p
s
t
h
o
u
g
h
t
t
o
b
e
r
e
s
p
o
n
s
i
b
l
e
f
o
r
r
e
c
u
r
r
e
n
c
e
(
e
.
g
.
,
g
a
s
t
r
o
c
n
e
m
i
u
s
,
s
o
l
e
u
s
,
a
n
d
t
i
b
i
a
l
i
s
)
F
o
o
t
a
s
s
e
s
s
m
e
n
t
v
i
a
t
h
e
H
a
r
r
o
l
d
c
l
a
s
s
i
ﬁ
c
a
t
i
o
n
A
l
l
3
p
a
t
i
e
n
t
s
h
a
d
m
a
r
k
e
d
c
o
r
r
e
c
t
i
o
n
i
n
d
e
f
o
r
m
i
t
y
f
o
l
l
o
w
i
n
g
i
n
j
e
c
t
i
o
n
a
n
d
c
a
s
t
s
N
o
n
e
I
V
D
e
l
g
a
d
o
e
t
a
l
.
,
2
0
0
0
[
4
1
]
C
a
s
e
s
t
u
d
y
N
=
4
p
a
t
i
e
n
t
s
w
i
t
h
s
e
v
e
r
e
c
l
u
b
f
o
o
t
(
D
i
m
e
g
l
i
o
g
r
a
d
e
I
V
)
,
w
h
o
n
o
l
o
n
g
e
r
r
e
s
p
o
n
d
e
d
t
o
p
h
y
s
i
c
a
l
t
h
e
r
a
p
y
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
.
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
i
n
j
e
c
t
i
o
n
i
n
t
o
t
h
e
g
a
s
t
r
o
c
n
e
m
i
u
s
a
n
d
/
o
r
p
o
s
t
e
r
i
o
r
t
i
b
i
a
l
m
u
s
c
l
e
s
(
i
)
D
o
s
e
:
r
a
n
g
e
1
.
2
U
–
6
.
2
U
/
k
g
b
o
d
y
w
e
i
g
h
t
,
d
e
p
e
n
d
i
n
g
o
n
s
e
v
e
r
i
t
y
a
n
d
m
u
s
c
l
e
t
y
p
e
.
(
i
i
)
M
u
s
c
l
e
w
a
s
i
d
e
n
t
i
ﬁ
e
d
v
i
a
e
l
e
c
t
r
i
c
a
l
s
t
i
m
u
l
a
t
i
o
n
(
t
i
b
i
a
)
o
r
d
i
r
e
c
t
e
x
a
m
i
n
a
t
i
o
n
(
g
a
s
t
r
o
c
n
e
m
i
u
s
)
.
Q
u
a
n
t
i
t
a
t
i
v
e
m
e
a
s
u
r
e
m
e
n
t
s
b
e
f
o
r
e
a
n
d
a
f
t
e
r
t
r
e
a
t
m
e
n
t
:
A
n
k
l
e
R
O
M
:
d
e
g
r
e
e
o
f
d
o
r
s
i
ﬂ
e
x
i
o
n
a
n
d
f
o
o
t
e
v
e
r
s
i
o
n
F
o
r
2
/
4
p
a
t
i
e
n
t
s
,
B
T
X
-
A
w
i
t
h
p
h
y
s
i
c
a
l
t
h
e
r
a
p
y
h
a
d
a
l
o
n
g
-
t
e
r
m
p
o
s
i
t
i
v
e
e
ﬀ
e
c
t
2
/
4
p
a
t
i
e
n
t
s
r
e
q
u
i
r
e
d
s
u
r
g
i
c
a
l
r
e
l
e
a
s
e
a
f
t
e
r
B
T
X
-
A
a
n
d
p
h
y
s
i
c
a
l
t
h
e
r
a
p
y
N
o
n
e
I
V8 International Journal of Pediatrics
T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
A
u
t
h
o
r
,
y
e
a
r
S
t
u
d
y
d
e
s
i
g
n
P
o
p
u
l
a
t
i
o
n
I
n
t
e
r
v
e
n
t
i
o
n
a
n
d
a
d
m
i
n
i
s
t
r
a
t
i
o
n
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
A
d
v
e
r
s
e
e
v
e
n
t
s
A
A
N
l
e
v
e
l
o
f
e
v
i
d
e
n
c
e
I
d
i
o
p
a
t
h
i
c
t
o
e
w
a
l
k
i
n
g
E
n
g
s
t
r
¨
o
m
e
t
a
l
.
,
2
0
1
0
[
4
2
]
F
o
l
l
o
w
-
u
p
s
t
u
d
y
N
=
1
5
p
a
t
i
e
n
t
s
(
a
g
e
r
a
n
g
e
:
5
–
1
3
y
)
m
e
d
i
a
n
a
g
e
(
9
y
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
A
f
t
e
r
i
n
j
e
c
t
i
o
n
,
c
h
i
l
d
r
e
n
/
p
a
r
e
n
t
s
w
e
r
e
i
n
s
t
r
u
c
t
e
d
t
o
s
t
r
e
t
c
h
t
h
e
c
a
l
f
5
x
/
w
e
e
k
a
n
d
w
a
l
k
o
n
h
e
e
l
s
a
t
l
e
a
s
t
5
0
s
t
e
p
s
/
d
a
y
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
b
i
l
a
t
e
r
a
l
i
n
j
e
c
t
i
o
n
i
n
t
o
4
s
i
t
e
s
i
n
e
a
c
h
c
a
l
f
u
n
d
e
r
e
l
e
c
t
r
o
m
y
o
g
r
a
m
a
m
p
l
i
ﬁ
e
r
g
u
i
d
a
n
c
e
D
o
s
e
:
6
U
/
k
g
,
m
a
x
i
m
u
m
o
f
4
0
0
U
(
i
)
3
D
g
a
i
t
a
n
a
l
y
s
i
s
(
p
r
e
,
3
w
e
e
k
s
,
3
,
6
,
a
n
d
1
2
m
o
n
t
h
s
p
o
s
t
)
.
(
i
i
)
C
l
a
s
s
i
ﬁ
c
a
t
i
o
n
o
f
t
o
e
w
a
l
k
i
n
g
s
e
v
e
r
i
t
y
(
p
r
e
,
1
2
m
o
n
t
h
s
p
o
s
t
)
.
(
i
i
i
)
P
a
r
e
n
t
s
r
a
t
e
d
t
h
e
p
e
r
c
e
i
v
e
d
a
m
o
u
n
t
o
f
t
o
e
w
a
l
k
i
n
g
(
p
r
e
,
6
a
n
d
1
2
m
o
n
t
h
p
o
s
t
)
.
(
i
)
S
i
g
n
i
ﬁ
c
a
n
t
i
m
p
r
o
v
e
m
e
n
t
o
n
g
a
i
t
a
n
a
l
y
s
i
s
i
n
1
1
/
1
1
c
h
i
l
d
r
e
n
a
t
1
2
m
o
n
t
h
s
.
(
i
i
)
9
/
1
4
c
h
i
l
d
r
e
n
d
i
s
p
l
a
y
e
d
i
m
p
r
o
v
e
m
e
n
t
o
n
s
e
v
e
r
i
t
y
c
l
a
s
s
i
ﬁ
c
a
t
i
o
n
.
(
i
i
i
)
P
a
r
e
n
t
s
r
e
p
o
r
t
e
d
t
h
a
t
3
/
1
1
c
h
i
l
d
r
e
n
c
o
m
p
l
e
t
e
l
y
c
e
a
s
e
d
t
o
e
w
a
l
k
i
n
g
a
t
1
2
m
o
n
t
h
s
.
P
a
r
e
n
t
s
o
f
3
c
h
i
l
d
r
e
n
r
e
p
o
r
t
e
d
m
o
d
e
r
a
t
e
p
a
i
n
i
n
c
a
l
f
m
u
s
c
l
e
f
o
r
2
-
3
w
e
e
k
s
a
f
t
e
r
i
n
j
e
c
t
i
o
n
I
I
I
B
r
u
n
t
e
t
a
l
.
,
2
0
0
4
[
4
3
]
F
o
l
l
o
w
-
u
p
s
t
u
d
y
N
=
5
p
a
t
i
e
n
t
s
,
a
g
e
r
a
n
g
e
3
.
3
–
6
.
3
y
(
m
e
a
n
=
4
.
3
y
)
.
I
n
t
e
r
v
e
n
t
i
o
n
:
b
i
l
a
t
e
r
a
l
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
i
n
j
e
c
t
i
o
n
,
p
h
y
s
i
c
a
l
t
h
e
r
a
p
y
2
x
/
w
e
e
k
,
a
n
d
h
o
m
e
p
r
o
g
r
a
m
.
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
g
a
s
t
r
o
c
n
e
m
i
u
s
a
n
d
s
o
l
e
u
s
m
u
s
c
l
e
s
u
n
d
e
r
E
M
G
g
u
i
d
a
n
c
e
.
D
o
s
e
:
1
2
U
/
k
g
,
m
a
x
i
m
u
m
4
0
0
U
G
a
i
t
a
n
a
l
y
s
i
s
(
p
r
e
,
m
e
a
n
2
0
d
a
y
s
p
o
s
t
,
a
n
d
1
2
m
o
n
t
h
s
p
o
s
t
)
A
n
k
l
e
E
M
G
p
a
t
t
e
r
n
d
u
r
i
n
g
g
a
i
t
i
s
n
o
r
m
a
l
i
z
e
d
a
n
d
a
m
o
r
e
n
o
r
m
a
l
f
o
o
t
-
s
t
r
i
k
e
p
a
t
t
e
r
n
i
s
o
b
t
a
i
n
e
d
P
o
s
t
i
n
j
e
c
t
i
o
n
i
m
p
r
o
v
e
m
e
n
t
w
a
s
m
a
i
n
t
a
i
n
e
d
a
t
1
2
m
o
n
t
h
s
N
o
t
r
e
p
o
r
t
e
d
I
I
I
J
a
c
k
s
e
t
a
l
.
,
2
0
0
4
[
4
4
]
F
o
l
l
o
w
-
u
p
s
t
u
d
y
N
=
1
0
p
a
t
i
e
n
t
s
w
i
t
h
p
r
e
v
i
o
u
s
l
y
f
a
i
l
e
d
t
r
e
a
t
m
e
n
t
f
o
r
t
o
e
w
a
l
k
i
n
g
,
a
g
e
r
a
n
g
e
2
–
1
7
y
I
n
t
e
r
v
e
n
t
i
o
n
:
b
i
l
a
t
e
r
a
l
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
i
n
j
e
c
t
i
o
n
,
s
h
o
r
t
l
e
g
w
a
l
k
i
n
g
c
a
s
t
s
a
f
t
e
r
i
n
j
e
c
t
i
o
n
f
o
r
7
d
a
y
s
,
A
F
O
a
n
d
h
o
m
e
s
t
r
e
t
c
h
i
n
g
p
r
o
g
r
a
m
,
a
n
d
e
l
e
c
t
r
i
c
a
l
s
t
i
m
u
l
a
t
i
o
n
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
g
a
s
t
r
o
c
n
e
m
i
u
s
a
n
d
s
o
l
e
u
s
m
u
s
c
l
e
s
D
o
s
e
:
1
0
U
/
k
g
P
r
e
a
n
d
1
-
,
3
-
,
6
-
a
n
d
1
2
m
o
n
t
h
s
p
o
s
t
:
(
i
)
O
b
s
e
r
v
e
d
g
a
i
t
.
(
i
i
)
R
O
M
a
t
a
n
k
l
e
,
k
n
e
e
,
a
n
d
h
i
p
.
(
i
i
i
)
P
a
r
e
n
t
r
e
p
o
r
t
o
f
L
o
w
e
r
E
x
t
r
e
m
i
t
y
F
u
n
c
t
i
o
n
A
s
s
e
s
s
m
e
n
t
T
e
s
t
.
A
l
l
1
0
c
h
i
l
d
r
e
n
h
a
d
r
e
s
o
l
u
t
i
o
n
o
f
t
o
e
w
a
l
k
i
n
g
a
t
3
m
o
n
t
h
s
a
f
t
e
r
t
h
e
i
n
i
t
i
a
l
i
n
j
e
c
t
i
o
n
O
n
e
c
h
i
l
d
r
e
q
u
i
r
e
d
r
e
p
e
a
t
i
n
j
e
c
t
i
o
n
w
i
t
h
p
h
y
s
i
c
a
l
t
h
e
r
a
p
y
a
f
t
e
r
w
h
i
c
h
t
o
e
w
a
k
i
n
g
r
e
s
o
l
v
e
d
I
m
p
r
o
v
e
m
e
n
t
s
i
n
o
v
e
r
a
l
l
f
u
n
c
t
i
o
n
N
o
n
e
I
I
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T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
A
u
t
h
o
r
,
y
e
a
r
S
t
u
d
y
d
e
s
i
g
n
P
o
p
u
l
a
t
i
o
n
I
n
t
e
r
v
e
n
t
i
o
n
a
n
d
a
d
m
i
n
i
s
t
r
a
t
i
o
n
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
A
d
v
e
r
s
e
e
v
e
n
t
s
A
A
N
l
e
v
e
l
o
f
e
v
i
d
e
n
c
e
L
o
w
e
r
l
i
m
b
l
e
n
g
t
h
e
n
i
n
g
H
a
m
d
y
e
t
a
l
.
,
2
0
0
9
[
4
5
]
M
u
l
t
i
c
e
n
t
e
r
R
C
T
N
=
5
2
p
a
t
i
e
n
t
s
w
h
o
u
n
d
e
r
w
e
n
t
d
i
s
t
r
a
c
t
i
o
n
o
s
t
e
o
g
e
n
e
s
i
s
a
n
d
l
o
w
e
r
l
i
m
b
l
e
n
g
t
h
e
n
i
n
g
(
a
g
e
r
a
n
g
e
:
5
–
2
1
y
)
(
m
e
a
n
=
1
3
.
7
y
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
o
r
p
l
a
c
e
b
o
.
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
s
i
n
g
l
e
i
n
j
e
c
t
i
o
n
i
n
t
o
a
ﬀ
e
c
t
e
d
m
u
s
c
l
e
g
r
o
u
p
,
d
u
r
i
n
g
s
u
r
g
i
c
a
l
p
r
o
c
e
d
u
r
e
.
D
o
s
e
:
1
0
U
/
k
g
b
o
d
y
w
e
i
g
h
t
,
u
p
t
o
a
m
a
x
i
m
u
m
o
f
4
0
0
U
o
f
B
T
X
-
A
,
a
s
r
e
c
o
m
m
e
n
d
e
d
b
y
F
D
A
P
a
i
n
,
m
e
d
i
c
a
t
i
o
n
u
s
e
,
q
u
a
l
i
t
y
o
f
l
i
f
e
,
a
n
d
f
u
n
c
t
i
o
n
a
l
m
o
b
i
l
i
t
y
C
o
m
p
a
r
e
d
t
o
p
l
a
c
e
b
o
,
B
T
X
-
A
g
r
o
u
p
h
a
d
(
i
)
l
o
w
e
r
P
a
i
n
a
t
m
i
d
d
i
s
t
r
a
c
t
i
o
n
.
(
i
i
)
l
e
s
s
p
a
r
e
n
t
e
r
a
l
p
a
i
n
m
e
d
i
c
a
t
i
o
n
a
f
t
e
r
s
u
r
g
e
r
y
.
(
i
i
i
)
h
i
g
h
e
r
q
u
a
l
i
t
y
o
f
l
i
f
e
a
t
3
o
f
t
h
e
5
t
i
m
e
p
o
i
n
t
s
.
(
i
v
)
h
i
g
h
e
r
f
u
n
c
t
i
o
n
a
l
m
o
b
i
l
i
t
y
s
c
o
r
e
s
.
(
v
)
T
h
e
s
e
r
e
s
u
l
t
s
w
e
r
e
n
o
t
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
.
N
o
n
e
r
e
l
a
t
e
d
t
o
B
T
X
-
A
I
N
e
o
n
a
t
a
l
b
r
a
c
h
i
a
l
p
l
e
x
u
s
p
a
l
s
y
E
z
a
k
i
e
t
a
l
.
,
2
0
1
0
[
4
6
]
F
o
l
l
o
w
-
u
p
s
t
u
d
y
3
5
p
a
t
i
e
n
t
s
w
i
t
h
p
o
s
t
e
r
i
o
r
s
h
o
u
l
d
e
r
s
u
b
l
u
x
a
t
i
o
n
o
r
d
i
s
l
o
c
a
t
i
o
n
(
1
7
b
o
y
s
,
1
8
g
i
r
l
s
)
;
m
e
a
n
a
g
e
a
t
t
r
e
a
t
m
e
n
t
5
.
7
m
(
3
–
1
6
m
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
i
n
t
o
t
h
e
i
n
t
e
r
n
a
l
r
o
t
a
t
o
r
m
u
s
c
l
e
s
,
c
l
o
s
e
d
r
e
d
u
c
t
i
o
n
,
a
n
d
c
a
s
t
i
m
m
o
b
i
l
i
z
a
t
i
o
n
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
i
n
j
e
c
t
i
o
n
s
i
n
t
o
s
u
b
s
c
a
p
u
l
a
r
i
s
,
t
e
r
e
s
m
a
j
o
r
,
a
n
d
p
e
c
t
o
r
a
l
i
s
m
a
j
o
r
m
u
s
c
l
e
s
D
o
s
e
:
1
0
U
/
k
g
i
n
j
e
c
t
e
d
e
q
u
a
l
l
y
i
n
t
o
t
h
e
m
u
s
c
l
e
s
(
2
-
3
U
/
k
g
p
e
r
m
u
s
c
l
e
)
P
a
s
s
i
v
e
e
x
t
e
r
n
a
l
r
o
t
a
t
i
o
n
o
f
t
h
e
s
h
o
u
l
d
e
r
,
a
s
s
e
s
s
m
e
n
t
w
i
t
h
t
h
e
A
c
t
i
v
e
M
o
v
e
m
e
n
t
S
c
a
l
e
o
r
a
m
o
d
i
ﬁ
e
d
M
a
l
l
e
t
s
c
a
l
e
i
n
o
l
d
e
r
c
h
i
l
d
r
e
n
I
m
a
g
i
n
g
u
s
i
n
g
r
a
d
i
o
g
r
a
p
h
y
a
n
d
/
o
r
u
l
t
r
a
s
o
n
o
g
r
a
p
h
y
(
i
)
2
6
/
3
5
p
a
t
i
e
n
t
s
d
i
d
n
o
t
r
e
q
u
i
r
e
e
a
r
l
y
o
p
e
n
s
u
r
g
i
c
a
l
p
r
o
c
e
d
u
r
e
s
t
o
r
e
d
u
c
e
t
h
e
s
h
o
u
l
d
e
r
s
.
(
i
i
)
T
h
e
1
1
c
h
i
l
d
r
e
n
w
h
o
e
x
p
e
r
i
e
n
c
e
d
a
r
e
d
i
s
l
o
c
a
t
i
o
n
e
v
e
n
a
f
t
e
r
a
2
n
d
i
n
j
e
c
t
i
o
n
i
n
c
l
u
d
e
d
t
h
e
3
o
l
d
e
s
t
p
a
t
i
e
n
t
s
a
n
d
t
h
e
2
i
n
f
a
n
t
s
w
h
o
s
e
p
a
r
e
n
t
s
r
e
f
u
s
e
d
f
u
r
t
h
e
r
t
r
e
a
t
m
e
n
t
.
N
o
n
e
I
I
I
P
r
i
c
e
e
t
a
l
.
,
2
0
0
7
[
4
7
]
R
e
t
r
o
s
p
e
c
t
i
v
e
r
e
v
i
e
w
2
6
p
a
t
i
e
n
t
s
w
i
t
h
r
e
c
o
n
s
t
r
u
c
t
i
o
n
f
o
r
a
m
e
d
i
a
l
r
o
t
a
t
i
o
n
d
e
f
o
r
m
i
t
y
o
f
t
h
e
s
h
o
u
l
d
e
r
1
3
h
a
d
B
T
X
-
A
i
n
j
e
c
t
i
o
n
(
m
e
a
n
a
g
e
:
5
.
8
y
)
1
3
d
i
d
n
o
t
h
a
v
e
B
T
X
-
A
(
m
e
a
n
a
g
e
:
4
.
0
y
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
i
n
t
h
e
p
e
c
t
o
r
a
l
i
s
m
a
j
o
r
m
u
s
c
l
e
a
t
t
h
e
e
n
d
o
f
t
h
e
o
p
e
r
a
t
i
o
n
.
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
1
0
0
U
o
f
B
T
X
-
A
i
n
t
h
e
p
e
c
t
o
r
a
l
i
s
m
a
j
o
r
m
u
s
c
l
e
a
t
t
h
e
e
n
d
o
f
t
h
e
o
p
e
r
a
t
i
o
n
M
o
d
i
ﬁ
e
d
G
i
l
b
e
r
t
s
c
a
l
e
(
i
)
N
o
s
i
g
n
i
ﬁ
c
a
n
t
d
i
ﬀ
e
r
e
n
c
e
b
e
t
w
e
e
n
b
o
t
h
g
r
o
u
p
s
p
r
e
o
p
e
r
a
t
i
v
e
l
y
.
(
i
i
)
P
o
s
t
o
p
,
t
h
o
s
e
w
h
o
h
a
d
t
h
e
B
T
X
-
A
i
n
j
e
c
t
i
o
n
h
a
d
s
i
g
n
i
ﬁ
c
a
n
t
l
y
b
e
t
t
e
r
G
i
l
b
e
r
t
s
c
o
r
e
s
(
P
=
0
.
0
1
2
)
a
t
m
e
a
n
f
o
l
l
o
w
-
u
p
o
f
3
y
e
a
r
s
.
N
o
t
r
e
p
o
r
t
e
d
I
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T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
A
u
t
h
o
r
,
y
e
a
r
S
t
u
d
y
d
e
s
i
g
n
P
o
p
u
l
a
t
i
o
n
I
n
t
e
r
v
e
n
t
i
o
n
a
n
d
a
d
m
i
n
i
s
t
r
a
t
i
o
n
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
A
d
v
e
r
s
e
e
v
e
n
t
s
A
A
N
l
e
v
e
l
o
f
e
v
i
d
e
n
c
e
B
a
s
c
i
a
n
i
a
n
d
I
n
t
i
s
o
,
2
0
0
6
[
4
8
]
C
a
s
e
s
e
r
i
e
s
2
2
p
a
t
i
e
n
t
s
w
i
t
h
m
i
l
d
b
r
a
c
h
i
a
l
p
l
e
x
u
s
p
a
l
s
y
w
h
o
p
r
e
v
i
o
u
s
l
y
u
n
d
e
r
w
e
n
t
s
e
r
i
a
l
c
a
s
t
t
r
e
a
t
m
e
n
t
u
n
s
u
c
c
e
s
s
f
u
l
l
y
(
1
0
m
a
l
e
s
,
1
2
f
e
m
a
l
e
s
m
e
a
n
a
g
e
:
5
.
6
y
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
D
y
s
p
o
r
t
)
,
t
h
e
n
t
r
e
a
t
e
d
a
r
m
w
a
s
ﬁ
x
e
d
w
i
t
h
p
l
a
s
t
e
r
c
a
s
t
a
n
d
p
r
o
g
r
e
s
s
i
v
e
l
y
l
e
n
g
t
h
e
n
e
d
o
v
e
r
1
4
d
a
y
s
c
a
s
t
w
a
s
m
a
i
n
t
a
i
n
e
d
f
o
r
3
0
d
a
y
s
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
B
T
X
-
A
i
n
j
e
c
t
e
d
i
n
t
o
b
i
c
e
p
s
b
r
a
c
h
i
i
,
b
r
a
c
h
i
a
l
i
s
,
p
r
o
n
a
t
o
r
t
e
r
e
s
,
a
n
d
p
e
c
t
o
r
a
l
i
s
m
a
j
o
r
w
i
t
h
2
2
U
/
k
g
M
u
s
c
l
e
s
t
r
e
n
g
t
h
a
s
s
e
s
s
e
d
u
s
i
n
g
t
h
e
M
e
d
i
c
a
l
R
e
s
e
a
r
c
h
C
o
u
n
c
i
l
s
c
a
l
e
(
g
r
a
d
e
s
0
–
5
)
,
M
a
l
l
e
t
s
c
a
l
e
s
,
N
i
n
e
H
o
l
e
P
e
g
T
e
s
t
(
N
H
P
T
)
,
g
o
n
i
o
m
e
t
r
y
,
a
t
b
a
s
e
l
i
n
e
,
3
,
6
,
a
n
d
1
2
m
o
n
t
h
s
(
i
)
S
c
o
r
e
s
o
n
N
H
P
T
s
i
g
n
i
ﬁ
c
a
n
t
l
y
d
e
c
r
e
a
s
e
d
(
d
e
n
o
t
i
n
g
b
e
t
t
e
r
o
u
t
c
o
m
e
)
a
t
3
,
6
,
a
n
d
1
2
m
o
n
t
h
s
a
f
t
e
r
i
n
j
e
c
t
i
o
n
.
(
i
i
)
M
a
l
l
e
t
s
c
o
r
e
s
d
i
d
n
o
t
c
h
a
n
g
e
,
e
l
b
o
w
e
x
t
e
n
s
i
o
n
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
i
n
a
l
l
b
u
t
4
p
a
t
i
e
n
t
s
.
(
i
i
i
)
T
h
e
s
e
4
c
h
i
l
d
r
e
n
w
e
r
e
o
l
d
e
r
,
a
n
d
r
e
p
e
a
t
i
n
j
e
c
t
i
o
n
s
w
e
r
e
u
n
s
u
c
c
e
s
s
f
u
l
.
2
p
a
t
i
e
n
t
s
r
e
p
o
r
t
e
d
a
r
t
i
c
u
l
a
r
p
a
i
n
l
a
s
t
i
n
g
5
d
a
y
s
a
f
t
e
r
r
e
m
o
v
a
l
o
f
t
h
e
p
l
a
s
t
e
r
c
a
s
t
(
u
n
r
e
l
a
t
e
d
t
o
t
h
e
B
T
X
-
A
i
n
j
e
c
t
i
o
n
s
)
I
V
D
e
M
a
t
t
e
o
e
t
a
l
.
,
2
0
0
6
[
4
9
]
C
a
s
e
s
e
r
i
e
s
8
p
a
t
i
e
n
t
s
(
5
f
e
m
a
l
e
s
,
3
m
a
l
e
s
,
m
e
a
n
a
g
e
:
1
2
.
5
m
r
a
n
g
e
,
5
–
2
2
m
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
i
n
c
o
n
j
u
n
c
t
i
o
n
w
i
t
h
i
n
t
e
n
s
i
v
e
O
T
a
n
d
a
h
o
m
e
p
r
o
g
r
a
m
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
B
T
X
-
A
i
n
j
e
c
t
e
d
i
n
t
a
r
g
e
t
m
u
s
c
l
e
s
a
t
t
o
t
a
l
d
o
s
e
o
f
4
U
/
K
g
/
m
u
s
c
l
e
i
n
t
o
m
u
l
t
i
p
l
e
s
i
t
e
s
a
l
o
n
g
t
r
i
c
e
p
s
o
r
l
a
t
i
s
s
i
m
u
s
d
o
r
s
i
a
n
d
p
e
c
t
o
r
a
l
i
s
m
a
j
o
r
A
c
t
i
v
e
M
o
v
e
m
e
n
t
S
c
a
l
e
(
A
M
S
)
a
n
d
p
a
r
e
n
t
r
e
p
o
r
t
o
f
c
h
a
n
g
e
b
e
f
o
r
e
a
n
d
a
f
t
e
r
B
T
X
-
A
(
i
)
A
f
t
e
r
a
s
i
n
g
l
e
i
n
j
e
c
t
i
o
n
,
a
l
l
p
a
r
e
n
t
s
r
e
p
o
r
t
e
d
i
m
p
r
o
v
e
d
f
u
n
c
t
i
o
n
.
(
i
i
)
A
M
S
s
c
o
r
e
s
i
m
p
r
o
v
e
d
s
i
g
n
i
ﬁ
c
a
n
t
l
y
f
r
o
m
p
r
e
B
T
X
-
A
t
o
1
m
o
n
t
h
(
P
=
0
.
0
1
4
)
a
n
d
f
r
o
m
b
e
f
o
r
e
B
T
X
-
A
t
o
4
m
o
n
t
h
s
(
P
=
0
.
0
2
2
)
.
N
o
t
r
e
p
o
r
t
e
d
I
V
H
e
i
s
e
e
t
a
l
.
,
2
0
0
5
[
5
0
]
F
o
l
l
o
w
-
u
p
s
t
u
d
y
8
p
a
t
i
e
n
t
s
w
i
t
h
c
l
i
n
i
c
a
l
o
r
e
l
e
c
t
r
o
m
y
o
g
r
a
p
h
i
c
e
v
i
d
e
n
c
e
o
f
b
i
c
e
p
s
-
t
r
i
c
e
p
s
c
o
c
o
n
t
r
a
c
t
i
o
n
a
n
d
p
o
o
r
e
l
b
o
w
f
u
n
c
t
i
o
n
(
4
t
r
i
c
e
p
s
,
4
b
i
c
e
p
s
;
1
m
a
l
e
,
7
f
e
m
a
l
e
s
,
a
g
e
:
1
6
m
–
5
y
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
+
h
o
m
e
-
b
a
s
e
d
p
h
y
s
i
o
t
h
e
r
a
p
y
,
s
o
m
e
d
i
d
p
h
y
s
i
o
o
u
t
s
i
d
e
t
h
e
h
o
s
p
i
t
a
l
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
1
i
n
j
e
c
t
i
o
n
o
f
2
-
3
U
/
k
g
o
f
B
T
X
-
A
d
i
v
i
d
e
d
i
n
2
o
r
3
s
i
t
e
s
M
u
s
c
l
e
s
t
r
e
n
g
t
h
a
s
s
e
s
s
e
d
u
s
i
n
g
t
h
e
M
e
d
i
c
a
l
R
e
s
e
a
r
c
h
C
o
u
n
c
i
l
s
c
a
l
e
(
g
r
a
d
e
s
0
–
5
)
,
a
b
i
l
i
t
y
t
o
p
e
r
f
o
r
m
h
a
n
d
-
m
o
u
t
h
c
o
n
t
a
c
t
i
n
t
h
e
s
i
t
t
i
n
g
p
o
s
i
t
i
o
n
(
i
)
3
/
4
p
a
t
i
e
n
t
s
w
i
t
h
i
n
j
e
c
t
i
o
n
t
o
t
h
e
t
r
i
c
e
p
s
w
e
r
e
a
b
l
e
t
o
p
e
r
f
o
r
m
h
a
n
d
-
m
o
u
t
h
c
o
n
t
a
c
t
i
n
s
i
t
t
i
n
g
(
1
0
d
t
o
6
m
a
f
t
e
r
i
n
j
e
c
t
i
o
n
)
,
l
a
s
t
i
n
g
u
p
t
o
1
8
m
.
(
i
i
)
F
o
r
b
i
c
e
p
s
,
3
/
4
h
a
d
i
m
p
r
o
v
e
m
e
n
t
o
f
e
l
b
o
w
e
x
t
e
n
s
i
o
n
l
a
s
t
i
n
g
3
–
6
m
o
n
t
h
s
.
(
i
i
i
)
O
n
e
c
h
i
l
d
h
a
d
n
o
i
m
p
r
o
v
e
m
e
n
t
a
f
t
e
r
b
i
c
e
p
s
i
n
j
e
c
t
i
o
n
a
n
d
p
a
r
e
n
t
s
r
e
f
u
s
e
d
a
d
d
i
t
i
o
n
a
l
i
n
j
e
c
t
i
o
n
.
N
o
t
r
e
p
o
r
t
e
d
I
I
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T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
A
u
t
h
o
r
,
y
e
a
r
S
t
u
d
y
d
e
s
i
g
n
P
o
p
u
l
a
t
i
o
n
I
n
t
e
r
v
e
n
t
i
o
n
a
n
d
a
d
m
i
n
i
s
t
r
a
t
i
o
n
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
A
d
v
e
r
s
e
e
v
e
n
t
s
A
A
N
l
e
v
e
l
o
f
e
v
i
d
e
n
c
e
G
r
o
s
s
m
a
n
e
t
a
l
.
,
2
0
0
4
[
5
1
]
C
a
s
e
s
t
u
d
y
2
p
a
t
i
e
n
t
s
(
1
0
m
m
a
l
e
,
a
n
d
1
1
m
f
e
m
a
l
e
)
w
i
t
h
l
a
t
e
n
e
r
v
e
r
e
c
o
n
s
t
r
u
c
t
i
o
n
f
o
r
p
e
r
s
i
s
t
e
n
t
s
h
o
u
l
d
e
r
p
a
r
a
l
y
s
i
s
f
o
l
l
o
w
i
n
g
a
n
u
p
p
e
r
b
r
a
c
h
i
a
l
p
l
e
x
u
s
b
i
r
t
h
i
n
j
u
r
y
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
1
0
U
/
k
g
i
n
t
o
p
e
c
t
o
r
a
l
i
s
m
a
j
o
r
a
n
d
l
a
t
i
s
s
i
m
u
s
d
o
r
s
i
M
o
d
i
ﬁ
e
d
G
i
l
b
e
r
t
s
c
a
l
e
B
o
t
h
s
c
o
r
e
s
a
d
v
a
n
c
e
d
(
f
r
o
m
1
t
o
4
a
n
d
f
r
o
m
1
t
o
5
)
N
o
t
r
e
p
o
r
t
e
d
I
V
G
r
o
s
s
m
a
n
e
t
a
l
.
,
2
0
0
3
[
5
2
]
F
o
l
l
o
w
-
u
p
s
t
u
d
y
1
9
p
a
t
i
e
n
t
s
w
i
t
h
a
c
o
m
b
i
n
e
d
r
e
c
o
n
s
t
r
u
c
t
i
o
n
o
f
t
h
e
u
p
p
e
r
b
r
a
c
h
i
a
l
p
l
e
x
u
s
a
n
d
s
h
o
u
l
d
e
r
f
o
r
s
e
q
u
e
l
a
e
o
f
b
i
r
t
h
i
n
j
u
r
y
,
(
m
e
a
n
a
g
e
:
1
6
m
,
r
a
n
g
e
:
1
1
–
2
9
m
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
A
l
l
e
r
g
a
n
)
i
n
t
o
p
e
c
t
o
r
a
l
i
s
m
a
j
o
r
(
7
0
U
)
a
n
d
l
a
t
i
s
s
i
m
u
s
d
o
r
s
i
(
3
0
U
)
A
d
m
i
n
i
s
t
r
a
t
i
o
n
:
n
o
t
s
p
e
c
i
ﬁ
e
d
M
o
d
i
ﬁ
e
d
G
i
l
b
e
r
t
s
c
a
l
e
(
i
)
A
t
f
o
l
l
o
w
-
u
p
(
m
e
a
n
4
2
.
7
m
o
n
t
h
s
)
,
a
l
l
a
d
v
a
n
c
e
d
b
y
a
m
e
a
n
o
f
2
g
r
a
d
e
s
(
r
a
n
g
e
:
2
t
o
5
)
.
(
i
i
)
T
h
r
e
e
c
h
i
l
d
r
e
n
r
e
q
u
i
r
e
d
r
e
o
p
e
r
a
t
i
o
n
,
a
n
d
4
h
a
d
p
e
r
s
i
s
t
e
n
t
m
i
l
d
m
e
d
i
a
l
r
o
t
a
t
i
o
n
c
o
n
t
r
a
c
t
u
r
e
a
t
f
o
l
l
o
w
-
u
p
.
N
o
t
r
e
p
o
r
t
e
d
I
I
I
H
i
e
r
n
e
r
e
t
a
l
.
,
2
0
0
1
[
5
3
]
F
o
l
l
o
w
-
u
p
o
f
R
o
l
l
n
i
k
a
n
d
c
o
l
l
e
a
g
u
e
s
’
s
t
u
d
y
(
2
0
0
0
)
a
t
1
8
m
6
f
e
m
a
l
e
s
(
r
a
n
g
e
:
2
–
4
y
)
I
n
t
e
r
v
e
n
t
i
o
n
:
B
T
X
-
A
(
D
y
s
p
o
r
t
)
i
n
j
e
c
t
e
d
i
n
t
o
t
h
e
t
r
i
c
e
p
s
m
u
s
c
l
e
a
t
2
s
i
t
e
s
u
n
d
e
r
E
M
G
g
u
i
d
a
n
c
e
.
D
o
s
e
:
a
v
e
r
a
g
e
o
f
4
0
M
U
a
t
a
c
o
n
c
e
n
t
r
a
t
i
o
n
o
f
2
5
M
U
/
m
L
M
u
s
c
l
e
f
o
r
c
e
(
M
R
C
c
l
a
s
s
i
ﬁ
c
a
t
i
o
n
)
a
n
d
R
O
M
,
r
e
c
u
r
r
e
n
c
e
o
f
c
o
c
o
n
t
r
a
c
t
i
o
n
u
s
i
n
g
E
M
G
A
t
1
8
m
f
o
l
l
o
w
-
u
p
(
i
)
m
e
a
n
e
l
b
o
w
ﬂ
e
x
i
o
n
w
a
s
a
b
o
u
t
1
0
0
◦
(
r
a
n
g
e
:
8
0
–
1
2
0
◦
)
.
(
i
i
)
r
e
d
u
c
t
i
o
n
o
f
t
r
i
c
e
p
s
c
o
n
t
r
a
c
t
i
o
n
d
u
r
i
n
g
b
i
c
e
p
s
a
c
t
i
v
i
t
y
w
a
s
o
b
s
e
r
v
e
d
u
s
i
n
g
E
M
G
.
(
i
i
i
)
a
v
e
r
a
g
e
t
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with BTX-A for tightness in the left knee ﬂexors in order
to enable standing exercises. Knee range of motion was
increased by 20degrees following injection, with no side-
eﬀects. The child’s posture in the standing frame was
controlled more easily. The knee range of motion decreased
by 15 degrees at 5 months after injection. BTX-A may be
indicated in children with Duchenne muscular dystrophy
when temporary improvement of range of motion is needed
to minimize knee contracture and encourage exercises for
muscle stretching, prevention of osteoporosis, and retaining
lung function.
3.4. Idiopathic Clubfoot. Five articles were included. The ﬁrst
study by Delgado and colleagues [41] included four patients
who had severe clubfoot deformities and rapidly reached a
plateau following physical therapy. BTX-A injections helped
most of the patients, despite their severe deformity, allowing
two of them to avoid surgery. The remaining two patients
had a demyelinating neuropathy and did not respond to
BTX-A treatment. Another study by Mitchell and colleagues
[40] reported on three children under the age of 13 months
who had a recurrence of their deformity after surgery and
found a marked improvement of the deformity following
BTX-A injection and application of molded plaster casts.
The largest study by Alvarez and colleagues [37, 38] included
51 children. Following Ponseti-type manipulations, casting,
and BTX-A injection, all but one child improved in terms of
dorsiﬂexion and a decrease in the severity of the deformity
was noted. Bracing was provided to maintain the correction.
At the ﬁve-year follow-up visit, 48% (31 of 65 clubfeet)
successfully responded to a single BTX-A injection and
experienced no recurrence over the follow-up period. At
least one repeat BTX-A injection was required in 34 clubfeet,
and surgery was required in 10clubfeet. These four studies
found a positive eﬀect of BTX-A as an adjunct to manip-
ulation, casting, and physical therapy to correct muscle
imbalance and to correct recurrent deformity in idiopathic
clubfoot. All ﬁve studies concluded that BTX-A may be an
eﬀective and safe treatment alternative and can decrease
the number of patients requiring surgery. A limitation of
these four studies is that they did not include a control
group and that the results cannot be attributed solely to
BTX-A as other treatment modalities were used. Cummings
and colleagues [39] conducted a randomized double-blind
controlledtrialon20infants(32clubfeet)comparingasingle
BTX-A injection to placebo following serial manipulation
and casting according to the Ponseti technique. The study
found no signiﬁcant diﬀerence in time of correction, need
for tenotomy, or relapse between both groups. However, this
trial included a small sample size and low BTX-A dosage
that may have compromised positive ﬁndings of BTX-A.
No adverse events were reported following BTX-A injections
in children with clubfoot. In order to address the need for
additional BTX-A injections, a larger trial is required with
r e g u l a rf o l l o w - u pa sw e l la sag o o dm a i n t e n a n c e - b r a c i n g
program, so as to provide each child with an individualized
treatment. The exact dose and number of injections have not
been established and may vary among individuals.
3.5. Idiopathic Toe Walking. Three studies [42–44]r e p o r t e d
improvement in gait pattern, function, and decreased toe
walkingseverityfollowingBTX-Ainjectiontogastrocnemius
and soleus muscles. Improvements were maintained at
12months. In addition to the BTX-A injection, children
also received a home exercise program, physical therapy, and
orthotics. Further studies are needed to evaluate whether
repeated injections and BTX treatment in combination with
othertreatmentinterventions (suchasorthotics and physical
therapy) improve outcome.
3.6. Legg-Calv´ e-Perthes Disease. No studies were found.
3.7. Lower Limb Lengthening. One study [45] met the inclu-
sion criteria. This was a pilot randomized controlled trial
comparing the eﬀects of BTX-A injection versus placebo
at the time of surgery. Fifty-two children with limb length
discrepancies of various etiologies, as well as children with
surgical correction of clubfoot deformities, were included.
Findings showed that compared to placebo, the BTX-A
group had a trend for lower pain at middistraction, less
parenteral pain medication after-surgery, higher functional
mobility scores, and better quality of life at three of ﬁve
time points, although these diﬀerences were not statistically
signiﬁcant. No adverse events related to the BTX-A injection
were reported, indicating that BTX-A may be safe and
eﬀective in alleviating pain, improving functional mobility
and quality of life in children undergoing lower limb
lengtheningand/ordeformitycorrection.Futurestudieswith
larger sample sizes are required and with homogeneous
study populations to verify whether BTX-A injections are
beneﬁcial at the time of surgery in these children.
3.8. Neonatal Brachial Plexus Palsy. Ten studies [46–55]
reported on the outcomes of using BTX-A, in which one
study by Hierner and colleagues [53]w a saf o l l o w - u p
report of the previous study by Rollnik and colleagues [55].
Although all children were diagnosed with NBPP, there
were a number of variations between studies in the speciﬁc
mechanism of injury and in the underlying limitations, such
as in severity of biceps-triceps cocontractions, persistence in
shoulder paralysis, medial rotation deformity of the shoul-
der, response to serial cast treatment, and posterior shoulder
subluxation or dislocation. The most commonly injected
muscles were pectoralis major, latissimus dorsi, and triceps.
However, diﬀerent muscle injection sites were used across
the studies, indicating an individualized protocol according
to each child’s condition and needs. Four studies reported
administering additional BTX-A injections, as needed. All
ten studies reported positive outcomes following BTX-A
injections, including improved ability to make hand-to-
mouth movements, avoidance of open surgical procedures,
improved active shoulder abduction and elbow extension,
better functional scores, and reduction of triceps cocontrac-
tionsduringelbowﬂexion.Twostudies[46,48]reportedthat
those children who did not experience improved outcomes
following BTX-A injections were older. Desiato and Risina
[54] found that the gain in shoulder abduction was directly14 International Journal of Pediatrics
related to younger age (r = 0.6). Transient weakness was
reported in a 6-year-old female [54] and mild to moderate
discomfort at the injection site was reported in two children
[53]. Four studies reported no severe adverse event related
to the BTX-A injections. Adverse events were not reported
in four studies. These ﬁndings indicate that BTX-A may be a
promising treatmentmodality in youngchildren withNBPP;
however, stronger methodologies are required to conﬁrm the
eﬀectiveness of BTX-A for this condition.
4. Discussion
The objectives of this systematic review were to establish
the evidence on the eﬀectiveness of BTX-A in several
musculoskeletal conditions in children and to show whether
these studies reported improved functional outcome. Out of
the 24 studies reviewed, only two randomized clinical trials
were conducted, one in children with clubfeet [39] and the
other in children undergoing lower limb lengthening [45].
Most studies were case studies with small sample sizes and
no control group. Furthermore, treatment of children with
musculoskeletal conditions is often multimodal, including
bracing, casting, rehabilitation, and home programs. There-
fore, attributing the improvements in outcome to a single
intervention, such as BTX-A, is not straightforward.
A recent systematic review on the indications for the
use of BTX-A treatment for children with NBPP was con-
ducted by Gobets and colleagues [56]. They included 10
full-text papers and six congress abstracts, involving 343
children. Four groups of indications were identiﬁed: internal
rotation/adduction contracture of the shoulder, limited
active elbow ﬂexion, limited active elbow extension, and
pronation contracture of the lower arm. Overall, positive
results were reported for all except the indication for
limited active elbow extension. However, only one study was
comparative in nature; all others were classiﬁed as having
a low level of evidence. There was a large variation in
outcome measures. These authors conclude that multicentre
randomized controlled trials are needed to provide better
evidence of BTX-A in this population.
Several factors speciﬁc to BTX-A injections may produce
inter- and intrastudy variations. These factors include the
diﬀerent dosages and commercial sources of BTX-A used
across the diﬀerent studies. Two brands of BTX-A were
used across the 24 studies (Allergan and Dysport). BTX-
A brand was not always speciﬁed in the reviewed studies
and this information was made available in several cases by
contactingtheauthors.Thesetwopreparationsshouldnotbe
used interchangeably, either in terms of predicting outcome
or in determining doses to be used. Though the units are
not interchangeable, various published reports support a
conversion ratio from 1:5 to 1:3. The technique used to
identify which muscle groups will be injected also varied
(palpation technique, electrical stimulation, etc.). Indeed,
diﬀerent studies have used diﬀerent techniques and thus may
lead to varying outcomes following BTX-A injection. There
is no consensus as to the exact age at which a child with
a musculoskeletal condition should be ﬁrst administered
BTX-A. Age of injection varied across the diﬀerent studies
reviewed. However, several authors [46, 48, 54] found that
the younger children at the onset of BTX-A treatment for
NBPP beneﬁted most compared to older children. Another
factor to keep in mind is the need for administering
repeat BTX-A injections for sustained beneﬁt. Some authors
administered repeated BTX-A doses, whereas other authors
gave just one dose, even in cases when the children did not
demonstrate improved outcome following the initial BTX-
A injection. This may have been due to ﬁnancial and time
restrictions as repeated injections are both expensive and
time-consuming. Findings indicate that repeat BTX-A doses
appear safe in children with musculoskeletal conditions.
Lengthoffollow-updiﬀeredacrossstudies.Longerfollow-up
periods are required to inform health care providers whether
the beneﬁts of BTX-A are temporary and transient and, then
if indicated, at which time should an additional injection
be administered. Alvarez and colleagues [37]c o n d u c t e da
5-year follow-up of their original study [38]. They reported
that 48% of clubfeet were successfully corrected after a single
dose of BTX-A in 44 children. This was the longest follow-up
period among all the studies reviewed.
Serious adverse events related to BTX-A injection were
not reported in the studies included in this review. Minor
adverse events such as transient muscular weakness and
local discomfort at the injection site were reported in few
studies. While this may be suggestive of the clinical safety
of BTX-A, it is important to note that several studies did
not actually report on the presence or absence of adverse
events. Therefore, more rigor is required in reporting these
events to establish the safety of BTX-A in children with
musculoskeletal conditions.
5. Conclusions
BTX-A is a promising treatment adjunct in improving func-
tional outcomes in children with musculoskeletal conditions
by causing a ﬂaccid paralysis of the aﬀected muscles. Further
studies should include a prospective methodology, longer
follow-up periods, and comparison group and evaluate
whether repeated injections are required to improve the out-
come of children, thus providing evidence on the eﬀective-
ness and safety of this drug in children with musculoskeletal
conditions.
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